

VEGF R3/FLT4

Catalog # PVGS1817

Product Information

| | |
|-------------------------------------|---|
| Primary Accession Species | P35916-1 Human |
| Sequence | Tyr25-Ile776 |
| Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
| Endotoxin Level | Less than 1EU per μ g by the LAL method. |
| Biological Activity | Immobilized VEGF-C, His Tag at 1 μ g/ml (100 μ l/Well) on the plate can bind VEGF R3/FLT4 hFc Chimera, Human (Cat.No.: Z03968) |
| Expression System | HEK293 |
| Theoretical Molecular Weight | 111.3 kDa |
| Formulation | Lyophilized from a 0.22 μ m filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5). |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml. |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Additional Information

| | |
|--------------------------|--|
| Target Background | Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors. |
|--------------------------|--|

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.